Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +89.6%
S&P 500 total return (same window) +37.0%
Excess return +52.6%

Annualized: +66.9% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 96.8%
Technology 3.2%

Full portfolio 3 positions

05
Type Streak 8Q trend
DNLI Denali Therapeutics Inc. - Common Stock $49,144,027 91.90% 1,910,732 $6,697,973 Down ×6
SANA Sana Biotechnology, Inc. - Common Stock $2,637,619 4.93% 755,736 $461,099
EGHT 8x8 Inc - Common stock $1,694,354 3.17% 990,850 $49,543

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
DNLI Trimmed -300K +$6.7M
SANA Price move only +0 +$461K
EGHT Price move only +0 +$50K